Mizuho on Tuesday said the Federal Court of Appeals ruling in favor of Acadia Pharmaceuticals (ACAD) on Monday, upholding the validity of the ‘740 composition of matter patent, should provide further support that Acadia will likely maintain exclusivity of Nuplazid until the expiration of the patent on April 29, 2030. However, the stock price has already baked in this conclusion following the favorable January 2024 summary judgment and recently assumed Nuplazid exclusivity into February 2038 after the favorable district court ruling on the company’s ‘721 formulation patent for Nuplazid in May, which covers the 34mg capsule formulation, the analyst told investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals Wins Patent Case for NUPLAZID
- Acadia court ruling supports Nuplazid exclusivity into 2030, says Mizuho
- Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent
- Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan
- Acadia Pharmaceuticals price target raised to $23 from $18 at BofA